Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · January 19, 2024

Concomitant Use of Biphasic Insulin Aspart 30/70 With GLP-1 Receptor Agonist vs First-Generation Basal Insulin With GLP-1 Receptor Agonist in Type 2 Diabetes

Diabetic Medicine: A Journal of the British Diabetic Association

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetic Medicine: A Journal of the British Diabetic Association
Real-world study of the concomitant use of biphasic insulin as part 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes
Diabet. Med. 2023 Dec 13;[EPub Ahead of Print], M Davies, AC Alibegovic, G Anil, UC Braae, AB Jensen, RB Nordsborg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading